Skip to main content

Table 2 Significantly enriched signalling pathways associated to the validated differentially expressed miRNAs

From: MicroRNA profile in very young women with breast cancer

KEGG Pathway

FDR

Number of miRNAs

Putative target genes

Adherens junction

1.03×10−4

4

ACTB, WASL, RAC2, IGF1R, PTPRF, TJP1, CDH1, CSNK2B, FARP2, PTPRJ, SSX2IP, PTPRB, PVRL1

Steroid biosynthesis

1.49×10−4

2

SC5DL, DHCR24, CYP27B1

Glycosaminoglycan biosynthesis - chondroitin sulfate

2.23×10−3

2

CHPF

Dilated cardiomyopathy

2.23×10−3

4

ACTB, ADCY1, ITGB8, ITGB3, CACNG7, TTN, ADCY3, ITGA5, ITGB5, DMD, PRKACA, CACNA1C, CACNA2D2, IGF1, CACNA2D1, CACNA1D, PRKACB

Lysine degradation

0.014

3

PLOD3, ASH1L, SETD8, MLL2, MLL, SETD1A

Taste transduction

0.014

4

GNG13, SCNN1B, GNB1, PRKACA, SCNN1A, PRKACB

Cell adhesion molecules (CAMs)

0.035

3

NEGR1, ITGB8, MPZ, SDC3, CLDN19, CLDN11, PTPRF, CDH1, CD276, NRXN2, CD86, ICOSLG, NFASC, PVRL1, NLGN3

Calcium signaling pathway

0.035

4

PRKCA, ADCY1, ATP2B2, BDKRB2, ADCY3, ITPKB, SLC8A2, PDE1B, CACNA11, CAMK2A, NOS1, PRKACA, NTSR1, CACNA1C, PHKA1, MYLK3, CACNA1D, GRIN2A, PRKACB, CHRM1

Fc gamma R-mediated phagocytosis

0.036

2

PRKCA, WASL, RAC2, PLA2G4F, ASAP3, GSN, FCGR1A, MARCKS, PIP5K1A, PLD2, AKT3, VASP, MYO10, ARF6

Hypertrophic cardiomyopathy (HCM)

0.036

4

ACTB, ITGB8, ITGB3, CACNG7, TTN, ITGA5, ITGB5, DMD, CACNA1C, CACNA2D2, IGF1, CACNA2D1, CACNA1D

Arrhytmogenic right ventricular cardiomyopathy (ARVC)

0.039

3

ACTB, DSC2, ITGB8, ITGB3, CACNG7, ITGA5, ITGB5, DMD, CACNA1C, CACNA2D2, CACNA2D1, CACNA1D

Wnt signaling pathway

0.041

4

PRKCA, DVL3, WNT16, ROCK1, RAC2, VANGL1, PPP2CA, PPP2R5C, CAMK2A, WNT6, PRICKLE1, PPP2R5B, JUN, APC2, PPP2R1A, PRKACA, VANGL2, CSNK2B, WNT9A, PRKACB

  1. FDR refers to p-values adjusted by Benjamini & Hochberg’s False Discovery Rate. Number of miRNAs is the count of miRNAs involved in the pathway and targeting one or more genes of the pathway.
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us